SPONSOR
Betta Pharmaceuticals Co., Ltd.
Total Trials
2
Recruiting
2
Phases
Phase 1, Phase 2
Betta Pharmaceuticals Co., Ltd. is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Advanced Solid Tumor, Lymphoma, NSCLC, HCC.
The trial portfolio spans Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Betta Pharmaceuticals Co., Ltd.
How many clinical trials has Betta Pharmaceuticals Co., Ltd. sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Betta Pharmaceuticals Co., Ltd., of which 2 are actively recruiting participants. These trials cover conditions including Advanced Solid Tumor, Lymphoma, NSCLC. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Betta Pharmaceuticals Co., Ltd. research focus on?
Betta Pharmaceuticals Co., Ltd. clinical trials span Advanced Solid Tumor, Lymphoma, NSCLC, HCC, Adjuvant Drug Therapy, and additional conditions. The research pipeline includes Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Betta Pharmaceuticals Co., Ltd. clinical trial?
To participate in a Betta Pharmaceuticals Co., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Betta Pharmaceuticals Co., Ltd. trials with current recruitment status updated daily.
Clinical Trials by Betta Pharmaceuticals Co., Ltd.
NCT05341557 Phase 1
Recruiting
A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Advanced Solid Tumor
NCT07181499 Phase 2
Recruiting
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
NSCLC
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology